9.20
price down icon2.75%   -0.26
pre-market  Vorhandelsmarkt:  9.60   0.40   +4.35%
loading
Schlusskurs vom Vortag:
$9.46
Offen:
$9.51
24-Stunden-Volumen:
493.15K
Relative Volume:
0.62
Marktkapitalisierung:
$686.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.91%
1M Leistung:
-7.07%
6M Leistung:
-45.64%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$9.20
$10.02
1-Wochen-Bereich:
Value
$8.48
$10.02
52-Wochen-Spanne:
Value
$7.80
$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name
Firmenname
Bicara Therapeutics Inc
Name
Telefon
617-785-8308
Name
Adresse
245 MAIN STREET, CAMBRIDGE
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
BCAX's Discussions on Twitter

Vergleichen Sie BCAX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BCAX
Bicara Therapeutics Inc
9.20 686.07M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-23 Hochstufung Wells Fargo Underweight → Equal Weight
2025-04-17 Eingeleitet Wells Fargo Underweight
2025-02-06 Eingeleitet Wedbush Outperform
2024-12-06 Eingeleitet H.C. Wainwright Buy
2024-11-05 Eingeleitet Rodman & Renshaw Buy
2024-10-08 Eingeleitet Cantor Fitzgerald Overweight
2024-10-08 Eingeleitet Morgan Stanley Overweight
2024-10-08 Eingeleitet Stifel Buy
2024-10-08 Eingeleitet TD Cowen Buy
Alle ansehen

Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten

pulisher
Jun 12, 2025

Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals

Jun 12, 2025
pulisher
Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 09, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock - Investing.com

Jun 09, 2025
pulisher
Jun 06, 2025

Bicara Therapeutics Expands Boston Headquarters with New Lease - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

25,028 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Nuveen Asset Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Merus Raises $300m After ASCO Success - insights.citeline.com

Jun 04, 2025
pulisher
Jun 03, 2025

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald maintains overweight rating on Bicara stock By Investing.com - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald maintains overweight rating on Bicara stock - Investing.com

Jun 03, 2025
pulisher
Jun 02, 2025

Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Stifel reiterates Buy rating on Bicara Therapeutics stock - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Stifel reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Bicara presents promising early-stage data in head and neck cancers - The Business Journals

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - The Manila Times

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer - Nasdaq

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus ... - Enidnews.com

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses - GlobeNewswire

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire Inc.

Jun 01, 2025
pulisher
May 27, 2025

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - MSN

May 27, 2025
pulisher
May 27, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLC - Defense World

May 27, 2025
pulisher
May 26, 2025

PIZZA PIZZA ROYALTY CORP. ANNOUNCES MAY DIVIDEND and TIMING OF ANNUAL GENERAL MEETING - The Globe and Mail

May 26, 2025
pulisher
May 25, 2025

159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust Corp - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company - Defense World

May 25, 2025
pulisher
May 24, 2025

Stifel maintains Bicara stock Buy rating, $48 target post-ASCO - Investing.com Australia

May 24, 2025
pulisher
May 24, 2025

Stifel maintains Bicara stock Buy rating, $48 target post-ASCO By Investing.com - Investing.com Canada

May 24, 2025
pulisher
May 24, 2025

112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG - Defense World

May 24, 2025
pulisher
May 24, 2025

Bicara falls after early-stage trial data for head and neck cancer therapy - MSN

May 24, 2025
pulisher
May 24, 2025

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - MSN

May 24, 2025

Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)

Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Bicara Therapeutics Inc-Aktie (BCAX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Meisner Lara
Chief Legal Officer
Jun 16 '25
Sale
10.43
15,829
165,096
0
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):